Overview
Filgram 30 MU (Filgrastim) PFS is a recombinant human granulocyte-colony stimulating factor (G-CSF) developed to reduce the risk and duration of neutropenia in patients undergoing chemotherapy or bone marrow transplantation. Manufactured by Eskayef Pharmaceuticals Ltd., this pre-filled syringe formulation offers reliable neutrophil recovery, enhancing immune defense in patients at risk of infection. As a trusted oncology solution, Filgram is globally supplied by Saif Pharma to healthcare providers across more than 60 countries.
What is Filgrastim?
Filgrastim is a man-made form of G-CSF, a naturally occurring protein that stimulates the bone marrow to produce white blood cells, particularly neutrophils. Through its action on hematopoietic cells, Filgrastim accelerates neutrophil production and improves their functional activity, making it essential for patients facing neutropenia due to cancer treatments, bone marrow transplantation, or congenital conditions.
Indications
Filgram 30 MU is indicated for:
Chemotherapy-induced neutropenia in cancer patients
Bone marrow transplantation support
Acute Myeloid Leukemia (AML) patients undergoing induction or consolidation chemotherapy
Severe chronic neutropenia (congenital, idiopathic, cyclic)
Peripheral Blood Progenitor Cell (PBPC) mobilization for stem cell collection
HIV-associated neutropenia with persistent low white blood cell count
Mechanism of Action
Filgrastim binds to specific receptors on neutrophil progenitor cells in the bone marrow, promoting their proliferation, differentiation, and activation. This results in a rapid increase in circulating neutrophils, usually within 24 hours of administration. Neutrophil counts are dose-dependent and decrease to normal levels within 1–7 days after discontinuation. This mechanism helps boost immunity in patients susceptible to infections.
Dosage & Administration
Filgram 30 MU (Filgrastim) is administered either subcutaneously (SC) or intravenously (IV) based on the indication and patient’s response:
Chemotherapy-induced neutropenia: 5 mcg/kg/day SC or IV
Bone marrow transplant: 10 mcg/kg/day IV
Peripheral blood stem cell mobilization: 10 mcg/kg/day for 4–7 days
Congenital neutropenia: 12 mcg/kg/day in single or divided doses
Idiopathic/cyclic neutropenia: 5 mcg/kg/day
HIV-associated neutropenia: 1–4 mcg/kg/day; maintenance: 300 mcg/day
Note: All dosing must be under medical supervision. Regular CBC (complete blood count) monitoring is essential.
Side Effects
Most patients tolerate Filgram well, but some may experience:
Bone pain or musculoskeletal discomfort
Headache and fatigue
Nausea, vomiting, diarrhea
Injection site redness or swelling
Allergic reactions (rare)
Splenic enlargement or rupture (rare)
Mild thrombocytopenia
Transient elevation of liver enzymes or uric acid
Warnings & Precautions
Do not administer Filgram within 24 hours before or after chemotherapy.
Monitor blood counts twice per week during therapy.
Use cautiously in patients with myeloid malignancies.
Risk of splenic rupture exists – report any abdominal pain.
Limited data in pregnant or breastfeeding women – use only if benefits outweigh risks.
Not established in neonates or patients with autoimmune neutropenia of infancy.
Storage Instructions
Store at 2–8°C in a refrigerator
Do not freeze
Protect from light and keep in original packaging
Check expiry before use
Overdose Effects
Overdose may lead to excessive neutrophil proliferation or splenomegaly. Monitor blood counts and manage symptoms as needed. Risk of tumor progression cannot be excluded.
Reconstitution
Dilute only in 5% dextrose if necessary. Do not dilute to concentrations below 5 mcg/ml. Follow aseptic technique during preparation and administration.
Manufacturer: Eskayef Pharmaceuticals Ltd.
Eskayef Pharmaceuticals Ltd., part of the Transcom Group, is one of the leading pharmaceutical manufacturers in Bangladesh. With WHO-GMP certification and global recognition, Eskayef is known for producing high-quality medicines that are exported to over 40 countries. For more, visit www.skfbd.com.
Supplier: Saif Pharma
Saif Pharma is a leading oncology medicine supplier based in Bangladesh. Since 2014, Saif Pharma has provided high-quality cancer treatments to over 60 countries including the USA, Canada, UAE, India, Pakistan, Saudi Arabia, and China. Committed to affordability, quality, and access, Saif Pharma is a trusted global name in oncology care.
Conclusion
Filgram 30 MU (Filgrastim) PFS is an effective and trusted treatment for neutropenia in oncology and hematology care. Manufactured by Eskayef Pharmaceuticals Ltd. and distributed worldwide by Saif Pharma, Filgram helps boost immunity and reduce infection risk in vulnerable patients. It offers a reliable, safe, and efficient solution for managing neutropenia associated with cancer therapy, bone marrow transplant, HIV, and congenital conditions.
